Paclitaxel/Paclitaxel-albumin

PreclinicalSmall molecule

WWigen Biomedicine Technology (Shanghai) Co., Ltd.

Paclitaxel/Paclitaxel-albumin is one of 80 small molecule programs targeting Solid Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorRecruiting

Advanced Solid TumorsRecruiting

Solid TumorPreclinical

Recruiting

Advanced Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

3 2

Nubeqa

Bayer

Preclinical

2 3

DATROWAY

Daiichi Sankyo

Preclinical

1 4

Fludara

Sanofi

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Navmi

SSummit Therapeutics

Preclinical

1 10

Tulmimetostat

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

PreclinicalRecruiting

Solid Tumor

NCT06953323

Clinical

Trials by Indication[1]

Solid Tumor1 trial

A Dose-escalation, Dose-expansion and Efficacy Extension Phase I/II Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of WJB001 Combination Therapy in Patients With Advanced Solid Tumors

Recruiting·WWigen Biomedicine Technology (Shanghai) Co., Ltd.·Preclinical·NCT06953323·86 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paclitaxel/Paclitaxel-albumin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel/Paclitaxel-albumin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel/Paclitaxel-albumin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wigen Biomedicine Technology (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: WWigen Biomedicine Technology (Shanghai) Co., Ltd.

Paclitaxel/Paclitaxel-albumin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News